Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFIR 03: Alpelisib vs Ribociclib in HR+, HER2- Metastatic Breast Cancer
NCT05625087Phase 2Terminated
- Sponsor
- Unicancer
- Start
- Oct 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib in breast cancer, sponsored by Unicancer. Started Oct 2023; status: terminated.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05625087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05625087.